Summary. -Between 1973 and 1977,247 patients with malignant teratoma have been treated in two units in London. Seventeen have developed brain metastases, an overall incidence of 6 2%.
IN recent years, the prognosis for patients with malignant teratoma has been considerably improved by advances in chemotherapy as well as in combinedmodality treatment (Williams, 1977) . Prolonged survival is now recorded, even for cases with extensive metastases on presentation. However, several adverse factors, including bulky abdominal disease and high levels of gonadotrophin (HCG) are recognized (Quivey et al., 1977) . the development of overt brain metastases is also generally accepted as a sign of bad prognosis as they usually occur in the context of advanced and drug-resistant tumours.
A recent American series of 240 patients with testicular teratoma (Vugrin et al., 15 1978) showed that the subgroup of patients with trophoblastic tumours had a much higher predilection for developing brain deposits than other groups, reflecting their particularly aggressive nature. We have analysed information on the incidence of brain metastases in 274 patients with malignant teratoma treated consecutively in two referral centres in London between 1973 and 1977, using serum HCG measurements as an index of trophoblastic differentiation. Present chemotherapy has the potential to control and possibly eradicate these tumours, but the need to detect CNS involvement at an early stage may be crucial. We have therefore examined the possibility of using spinal-fluid HCC4 estimation as a tumour marker. Besides HCG, another index substance detected in the serum, which has proved useful in the diagnosis and management in malignant teratoma, is ca-foetoprotein (AFP; Kohn et al., 1976) and we have also analysed data on spinal-fluid AFP levels, to evaluate its possible role as a tumour marker of brain metastases.
One problem inherent in the use of tumour markers for localization of testicular tumours is the heterogeneous nature of the metastases which may arise. Differ Table. All 17 showed extra-lymphatic spread to lungs or liver or both, in addition to the cerebral deposits. In 12 cases there was clear evidence of progression of metastatic disease in other sites, chiefly the lungs, before the cerebral deposits were diagnosed. In the other 5 cases the brain metastases were responsible for the presenting symptoms of malignant disease. In the 12 patients who developed brain metastases after orchidectomy or biopsy of extra-gonadal tumour, the mean interval before diagnosis of the brain deposits was 8-7 months (range 5-31). During this period chemotherapy had been given to 9 patients and abdominal irradiation to 3. The median survival after diagnosis of cerebral metastases in the 17 cases was 6 weeks. Only one patient is currently alive and diseasefree, 12 months after completing treatment. This was based on a combined-modality approach, using extensive chemotherapy, surgery and radiotherapy, and the case is reported separately (Kaye et al., 1978) .
In 59 patients of the series (9 of whom had brain metastases) CSF was obtained at the same time as serum for analysis of HCG and AFP. Several of these patients underwent repeated lumbar punctures with administration of intrathecal methotrexate.
Where possible, aliquots of CSF specimens were taken for estimation of protein concentration and for microscopic examination. A8say method.-Radioimmunoassay with a pre-precipitated double-antibody method was used for measurement of both HCG and AFP (Kardana & Bagshawe, 1976) . All samples were measured in triplicate. CSF specimens containing red cells were centrifuged before analysis, and equilibration for protein content was carried out for all CSF measurements. Between 1973 and 1975, HCG was measured using antibody to the intact molecule. From 1975 to 1977 a greater degree of sensitivity was obtained by using an assay specific for the beta sub-unit of HCG: results being expressed in iu/l with a lower limit of sensitivity of 2 iu/l (0-5 ng/l).
AFP levels are expressed in Hug/l, with 10 jug/l as an arbitrary upper limit of normal. The results of AFP estimation of the serum and CSF specimens of 44 patients
RESULTS

Serum
Histological examination
In 8/17 patients with brain metastases, necropsy was performed, and in 1 other patient (M.P.) histological examination of the deposit removed by excision biopsy was possible.
In 4 of these 9 patients no identifiable tumour was present in the cerebral lesions; necrosis and haemorrhage were the predominant features. The serum: CSF ratios for HCG in these 4 cases before death were 1155, 1802, 24 and 10.
In only 2 of the remaining 5 patients with identifiable tumour in the brain deposits were prior CSF specimens obtained for HCG analysis. (Laterre et al., 1964) and these include an oc-globulin fraction with the biochemical properties of glycoprotein similar to those of AFP. There is therefore a possibility of cross-reactivity with a normal CSF constituent in the AFP assay, and results from a preliminary study on CSF specimens from patients with non-malignant neurological disease lend support to this hypothesis (Kaye & Bagshawe, 1979) .
CSF protein estimation and cytological examination generally do not contribute to the diagnosis of brain metastases. Analysis for other putative tumour markers in spinal fluid (Kaye & Bagshawe, 1979) has not been performed in this series of teratoma patients.
With regard to management, the poor survival figures indicate failure to control generalized metastatic disease, particularly in the lungs, in the majority of patients with brain metastases from malignant teratoma. However, the results of treatment for advanced disease continue to improve, particularly by the use of a combined-modality approach (Peckham et al., 1977) . Where metastatic disease in sites other than the brain has responded to treatment, an aggressive policy for residual cerebral metastases using chemotherapy, surgery and radiotherapy is justified.
An integral part of this approach would be early diagnosis of brain deposits in patients at high risk of developing them (those with high levels of HCG and progressive lung metastases). Our data indicate that at present this aim is most likely to be achieved by regular estimation of CSF levels of HCG.
